SCHEMBL14435274

SCHEMBL14435274

CC[C@@H](COc1cc(Cl)ccc1C1CCN(C(=O)[C@H](N)Cc2ccc(Cl)cc2F)CC1)N(C)C

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PROKR1 Q8TCW9 5/20 0.41
▸ ADAM17 P78536 2/20 0.39
▸ ADAMTS5 Q9UNA0 2/20 0.39
▸ MC4R P32245 8/20 0.39
▸ MC5R P33032 1/20 0.39
▸ MC3R P41968 1/20 0.39
▸ AKT1 P31749 1/20 0.37
▸ AKT2 P31751 1/20 0.37
▸ AKT3 Q9Y243 1/20 0.37
▸ HDAC8 Q9BY41 3/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14436420 0.88 AKT1 (0.44) PROKR1ADAM17ADAMTS5AKT1
SCHEMBL14435251 0.86 ADAM17 (0.39) PROKR1ADAM17ADAMTS5MC4RMC5R
SCHEMBL14435281 0.86 ADAM17 (0.39) PROKR1ADAM17ADAMTS5MC4RMC5R
SCHEMBL12713318 0.86 CALCA (0.41) PROKR1ADAM17ADAMTS5MC4RMC5R
SCHEMBL14435238 0.85 ADAM17 (0.43) PROKR1ADAM17ADAMTS5MC4RMC5R
SCHEMBL14435248 0.85 ADAM17 (0.43) PROKR1ADAM17ADAMTS5MC4RMC5R
SCHEMBL14435264 0.85 ADAM17 (0.40) PROKR1ADAM17ADAMTS5MC4RMC5R
SCHEMBL14435253 0.85 ADAM17 (0.40) PROKR1ADAM17ADAMTS5MC4RMC5R
SCHEMBL12713270 0.81 HTR7 (0.39) ADAM17ADAMTS5MC4RAKT1AKT2
SCHEMBL14435996 0.81 ADAM17 (0.43) PROKR1ADAM17ADAMTS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007096186-A1 SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-08-30 — — WO disclosed
Send feedback